The expression of CD123 on several populations of normal hematopoietic cells, including circulating B cells, myeloid progenitors, dendritic cells, and megakaryocytes raises concerns regarding potential on-target, off-tumor effects. This evidence concerns the gene IL3RA and neoplasm.